Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP001 Tregs in ALS
NCT06671236Phase 1Recruiting
- Sponsor
- Novabio Therapeutics
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sodium chlorite in amyotrophic lateral sclerosis (ALS), sponsored by Novabio Therapeutics. Primary endpoints: Treatment Related Adverse Events at 6 months and Maximum Tolerated Dose at 28 days. Started Nov 2024; status: recruiting.
02
Drugs
sodium chlorite
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06671236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671236.